Masa Hosomizu interviewed by Nikkei about Curi RMB Capital court challenge to Taisho Pharma's management buyout
Masa Hosomizu interviewed by Nikkei about Curi RMB Capital court challenge to Taisho Pharma's management buyout
RMB Japan Fund portfolio manager Masa Hosomizu was recently interviewed by Nikkei Asia about Curi RMB Capital's court filing against Taisho Pharmaceuticals' proposed management buyout offer. Hosomizu noted in the interview that the tender offer price is unfair and the firm is protecting minority shareholders' interests through this action.
Please click this link to see the RMB Japan Funds current top 10 holdings.
Mutual fund investing involves risk. Principal loss is possible.
)
)
)